Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.
The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.
Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.
The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.
Beyond Air (XAIR) disclosed an insider derivative change by CEO and Chairman Steven A. Lisi. On 11/03/2025, he canceled 164,778 warrants with a $7.586 exercise price and received a replacement warrant for 164,778 shares at $1.95. The warrant was originally issued on September 27, 2024, became exercisable on November 22, 2024, and will expire five years from November 22, 2024. Following these transactions, he directly holds 164,778 warrants.
Beyond Air (XAIR) announced new financing and equity arrangements. The company entered an equity purchase agreement with Streeterville Capital for up to $20,000,000 in common stock, subject to a resale registration becoming effective and while no balance remains on a related note. The company agreed to file the registration statement by November 24, 2025. Share sales are bounded by a 4.99% Beneficial Ownership Limitation and Nasdaq’s 19.99% cap unless stockholder approval or pricing conditions under Rule 5635(d) are met.
Beyond Air also issued a secured promissory note with a principal amount of $12,050,000, receiving net proceeds of $12,000,000. The note matures in 24 months, carries 15% annual interest with no accrual for the first 12 months, and guarantees $1,800,000 of interest. Collateral includes a $6,000,000 cash DACA via a new subsidiary, with step-down mechanics as principal is repaid.
The company amended a prior loan to add a $2,000,000 term loan and issued five-year warrants to purchase 512,821 shares at $1.95, while repricing certain 2024 warrants to $1.95. Separately, 726,618 employee and director stock options were repriced to $1.95.
Beyond Air, Inc. filed Amendment No. 1 to its shelf registration statement on Form S-3 primarily as a technical update. The amendment is described as being filed solely to revise Item 16 of Part II in order to add the legal opinion of Sichenzia Ross Ference Carmel LLP as Exhibit 5.1 and the related consent as Exhibit 23.3, while leaving all other parts of the registration statement unchanged.
The filing also restates the full exhibit list, which includes prior merger agreements, certificates of incorporation and amendments, multiple warrant and securities purchase agreements, loan and security agreements, equity incentive and compensation plans, and an at-the-market equity offering sales agreement. It concludes with signatures from the chief executive officer, chief financial officer, and directors, along with a power of attorney authorizing designated officers to sign future amendments related to this registration.
Beyond Air, Inc. (XAIR) filed an S-3 shelf registration that includes an At-The-Market (ATM) equity program with BTIG allowing up to $35,000,000 of Common Stock sales. The company agreed to pay the agent a 3.0% cash commission and reimburse certain expenses. Reported issuances under the ATM were 564,699 shares for $2.5 million during the quarter ended June 30, 2025, and 1,877,076 shares for $5.8 million from July 1, 2025 through September 24, 2025. The prospectus includes standard risk-factor language noting the company expects to incur losses for the next few years and lists typical commercialization, regulatory, intellectual property, personnel, and growth-management risks.
Beyond Air, Inc. filed an 8-K describing terms that limit the number of common shares issuable on exercise of certain warrants to prevent a holder from exceeding a stated "Beneficial Ownership Limitation." If an exercise would push the holder past that limit, the company will only issue the number of shares that keep the holder below the limit and will hold the remaining shares in abeyance until the holder notifies the company that issuance would comply with the limitation.
The filing lists exhibits including a Form of New Warrant, a Form of Inducement Letter, and a Press Release dated September 8, 2025. The filing also identifies Steven A. Lisi by name.
Beyond Air, Inc. filed a report describing that its subsidiary NeuroNOS Limited has been granted U.S. Food and Drug Administration Orphan Drug Designation for BA-101, its lead investigational therapy for treating glioblastoma. This status applies to serious rare diseases and can provide development incentives. The company released a press release with more details, furnished as an exhibit, and notes that this information is provided under Regulation FD and is not deemed filed for liability purposes or automatically incorporated into other securities law filings.
Beyond Air, Inc. filed a report describing that its subsidiary NeuroNOS Limited has been granted U.S. Food and Drug Administration Orphan Drug Designation for BA-101, its lead investigational therapy for treating glioblastoma. This status applies to serious rare diseases and can provide development incentives. The company released a press release with more details, furnished as an exhibit, and notes that this information is provided under Regulation FD and is not deemed filed for liability purposes or automatically incorporated into other securities law filings.
Robert Scott Goodman, a director of Beyond Air, Inc. (XAIR), received a grant of stock options on 08/14/2025. The option grant is for 3,750 stock options with an exercise price of $2.45 per share and an expiration date of 08/14/2035. The option vests 25% on December 31, 2025, with the remainder vesting in equal annual installments on each December 31 for the next three years. After the grant, the reporting person beneficially owns 5,750 shares of common stock, which includes an additional 2,000 stock split-adjusted shares noted in the filing.
Beyond Air, Inc. filed a current report to note that it has issued a press release announcing its financial results for the first quarter ended June 30, 2025. The company stated that the press release, dated August 12, 2025, is attached as Exhibit 99.1 and is incorporated by reference into this report. The information in this report and the attached press release is being furnished rather than filed under securities laws, which affects how it is treated for certain liability and incorporation purposes.